The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,006
Tone, M., Izumo, T., Awano, N., Kuse, N., Inomata, M., Jo, T., Yoshimura, H., Minami, J., Takada, K., Miyamoto, S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13187 · Cited by 88
Trefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M. N., Lardinois, D., Laubli, H. P., Uhlenbrock, F., & Zippelius, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02558-z · Cited by 88
Advances in the Treatment of Non–Small Cell Lung Cancer
Patel, S. A., & Weiss, J. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.010 · Cited by 92
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
Smit, J., Borm, F. J., Niemeijer, A.-L. N., Huisman, M. C., Hoekstra, O. S., Boellaard, R., Oprea‐Lager, D. E., Vugts, D. J., van Dongen, G. A. M. S., der Veen, B. J. D. W., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262473 · Cited by 89
Wang, X., Barrera, C., Bera, K., Viswanathan, V. S., Azarianpour-Esfahani, S., Koyuncu, C., Velu, P., Feldman, M. D., Yang, M., Fu, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3966 · Cited by 89
Immunotherapy-based combinations in metastatic NSCLC
Desai, A. P., & Peters, S. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102545 · Cited by 94
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
The interactions of paclitaxel with tumour microenvironment
Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 93
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 98
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 96
Herzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 92
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 94
Cortellini, A., Friedlaender, A., Banna, G. L., Porzio, G., Bersanelli, M., Cappuzzo, F., Aerts, J. G. J. V., Giusti, R., Bria, E., Cortinovis, D. L., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.010 · Cited by 86
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerPreprint
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 91
Sato, R., Imamura, K., Sakata, S., Ikeda, T., Horio, Y., Iyama, S., Akaike, K., Hamada, S., Jodai, T., Nakashima, K., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060762 · Cited by 88
The clinical significance of soluble PD-1 and PD-L1 in lung cancer
Hejleh, T. A., Furqan, M., Ballas, Z. K., & Clamon, G. H. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.08.009 · Cited by 85
Vilariño, N., Bruna, J., Bosch‐Barrera, J., Valiente, M., & Nadal, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102067 · Cited by 85
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 95
Modeling Cancer with Flies and Fish
Cagan, R. L., Zon, L. I., & White, R. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.013 · Cited by 91
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
Martínez, P., Peters, S., Stammers, T. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3904 · Cited by 82
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remón, J., Ahn, M., Girard, N., Johnson, M. L., Kim, D., Lopes, G. D. L., Jr., Pillai, R. N., Solomon, B., Villacampa, G. J., & Zhou, Q. H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.022 · Cited by 84
Metadherin enhances vulnerability of cancer cells to ferroptosis
Bi, J., Yang, S., Long, L., Dai, Q., Borcherding, N. C., Wagner, B. A., Buettner, G. R., Spitz, D. R., Leslie, K. K., Zhang, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1897-2 · Cited by 86
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Haratani, K., Yonesaka, K., Takamura, S., Maenishi, O., Kato, R., Takegawa, N., Kawakami, H., Tanaka, K., Hayashi, H., Takeda, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126598 · Cited by 85
Chardin, D., Paquet, M., Schiappa, R., Darcourt, J., Bailleux, C., Poudenx, M., Sciazza, A., Ilié, M., Benzaquen, J., Martin, N., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000645 · Cited by 83
Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 85
Zhang, X., Cheng, L., Gao, C., Chen, J., Liao, S., Zheng, Y., Xu, L., He, J., Wang, D., Fang, Z., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2405 · Cited by 91
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 87
Self-citationNanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Li, J., Zhu, L., & Kwok, H. F. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100904 · Cited by 89
Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.015 · Cited by 82
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 83
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 83
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 85
Kitagawa, S., Hakozaki, T., Kitadai, R., & Hosomi, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13483 · Cited by 81
Peng, L., Qin, B., Xiao, K., Xu, S., Yang, J., Zang, Y., Stebbing, J., & Xie, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781333 · Cited by 84
Liu, S. M., & Wu, Y.-L. L. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1833857 · Cited by 81
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
Portuguese, A. J., Tykodi, S. S., Blosser, C. D., Gooley, T., Thompson, J. A., & Hall, E. T. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7009 · Cited by 85
Wang, C., Qiao, W., Jiang, Y., Zhu, M., Shao, J., Wang, T., Liu, D., & Li, W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29371 · Cited by 83
Petrillo, L. A., El-Jawahri, A. R., Nipp, R. D., Lichtenstein, M. R., Durbin, S., Reynolds, K. L., Greer, J. A., Temel, J. S., & Gainor, J. F. (2020) · Cancer · doi:10.1002/cncr.32782 · Cited by 80
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 82
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00331-3 · Cited by 81
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Peters, S., Cho, B. C., Luft, A. V., Alatorre-Alexander, J., Geater, S. L., Лактионов, К. К., Trukhin, D. V., Kim, S., Ursol, G., Hussein, M., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1381 · Cited by 80
Self-citationInsinga, R. P., Vanness, D. J., Feliciano, J. L., Vandormael, K., Traoré, S., Ejzykowicz, F., & Burke, T. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571297 · Cited by 82
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Wu, H., Pan, Y., He, Y., Wang, Z., Guan, W., Chen, Y., Yao, Y., Shao, N., Xu, R., & Wang, F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01490 · Cited by 79
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Mamdani, H. M., & Jalal, S. I. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.582370 · Cited by 81
Huang, Z., Su, W., Lu, T., Wang, Y., Dong, Y., Qin, Y., Liu, D., Sun, L., & Jiao, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578091 · Cited by 79
Vega, D. M., Nishimura, K. K., Zariffa, N. M.-D., Thompson, J. C., Hoering, A., Cilento, V. J., Rosenthal, A., Anagnostou, V., Baden, J. F., Beaver, J. A., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00372 · Cited by 80
spaCI: deciphering spatial cellular communications through adaptive graph model
Tang, Z., Zhang, T., Yang, B., Su, J., & Song, Q. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac563 · Cited by 78
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 82
Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer · doi:10.1002/cncr.33885 · Cited by 75
Ozawa, Y., Amano, Y., Kanata, K., Hirotsugu, H., Matsui, T., Kakutani, T., Koyauchi, T., Tanahashi, M., Niwa, H., Yokomura, K., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1255-3 · Cited by 73
Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Gao, F., & Yang, C. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666191114110359 · Cited by 80
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 80
Ren, F., Zhao, T., Liu, B., & Pan, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s199176 · Cited by 76
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
Boesch, M., Baty, F., Albrich, W. C., Flatz, L., Rodriguez, R., Rothschild, S. I., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1988403 · Cited by 75
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C. M., Yamamoto, N., Cheng, Y., Moiseyenko, V. M., Summers, Y., Vynnychenko, I. O., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.223 · Cited by 80
Self-citationCriss, S. D., Mooradian, M. J., Watson, T. R., Gainor, J. F., Reynolds, K. L., & Kong, C. Y. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11952 · Cited by 76
Hai, J., Zhang, H., Zhou, J. R., Wu, Z., Chen, T., Papadopoulos, E., Dowling, C. M., Pyon, V., Pan, Y., Liu, J. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1627 · Cited by 74
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 76
Zarif, T. E., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., Rubinstein, P. G., Nonato, T. K., McKay, R. R., Li, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02459 · Cited by 75
Ready, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 77
Self-citationGalli, G., Triulzi, T., Proto, C., Signorelli, D., Imbimbo, M., Poggi, M. M., Fucà, G., Ganzinelli, M., Vitali, M., Palmieri, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.008 · Cited by 73
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Zaborowska-Szmit, M., Krzakowski, M. J., Kowalski, D. M., & Szmit, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051268 · Cited by 73
Self-citationPei, X., Chen, S., Long, X., Zhu, S., Qiu, B., Lin, K., Lü, F., Xu, J., Zhang, P., & Wu, Y. (2020) · Aging · doi:10.18632/aging.103392 · Cited by 71
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
Zhou, C., Hu, Y., Arkania, E., Kılıçkap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.004 · Cited by 72
Self-citationWang, J., Ma, Y., Lin, H., Wang, J., & Cao, B. (2024) · BMC Immunology · doi:10.1186/s12865-024-00599-y · Cited by 72
Management of Lung Cancer During the COVID-19 Pandemic
Singh, A. P., Berman, A. T., Marmarelis, M. E., Haas, A. R., Feigenberg, S. J., Braun, J., Ciunci, C. A., Bauml, J. M., Cohen, R. B., Kucharczuk, J. C., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00286 · Cited by 70
Dendritic Cell-Based Immunotherapy in Lung Cancer
Stevens, D., Ingels, J., Lint, S. V., Vandekerckhove, B., & Vermaelen, K. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620374 · Cited by 73
Shahriari, M., Taghdisi, S. M., Abnous, K., Ramezani, M., & Alibolandi, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.039 · Cited by 71
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 72
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 77
Identification of Key Genes Related to Lung Squamous Cell Carcinoma Using Bioinformatics Analysis
Gao, M., Kong, W., Huang, Z., & Xie, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082994 · Cited by 73
Dall’Olio, F. G., Gelsomino, F., Conci, N., Marcolin, L., Giglio, A. D., Grilli, G., Sperandi, F., Fontana, F., Terracciano, M., Fragomeno, B., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.005 · Cited by 70
Serpico, A. F., Visconti, R., & Grieco, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2567-0 · Cited by 70
Feng, H., Liu, K., Shen, X., Liang, J., Wang, C., Qiu, W., Cheng, X., & Zhao, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03111-7 · Cited by 66
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Privitera, G., Pugliese, D., Lopetuso, L. R., Scaldaferri, F., Neri, M., Guidi, L., Gasbarrini, A., & Armuzzi, A. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211006669 · Cited by 70
Zhang, J., Pan, Y., Shi, Q., Zhang, G., Jiang, L., Dong, X., Gu, K., Wang, H., Zhang, X., Yang, N., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12225 · Cited by 69
Wang, X., Semba, T., Manyam, G. C., Wang, J., Shao, S. H., Bertucci, F., Finetti, P., Krishnamurthy, S., Phi, L. T. H., Pearson, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn7983 · Cited by 69
Yang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05757-5 · Cited by 71
Nadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 70
Konen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 73
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., Grenda, A., Krawczyk, P. A., & Milanowski, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081915 · Cited by 71
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target
Nana, F. A., Vanderputten, M., & Ocak, S. (2019) · Cancers · doi:10.3390/cancers11111683 · Cited by 69
Huang, M., Lopes, G. D. L., Jr., Insinga, R. P., Burke, T. A., Ejzykowicz, F., Zhang, Y., & Feliciano, J. L. (2019) · Immunotherapy · doi:10.2217/imt-2019-0178 · Cited by 69
Okada, N., Matsuoka, R., Sakurada, T., Goda, M., Chuma, M., Yagi, K., Zamami, Y., Nishioka, Y., & Ishizawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70743-2 · Cited by 69
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
The Cognitive Effects of Radiotherapy for Brain Metastases
Lehrer, E. J., Jones, B. M., Dickstein, D. R., Green, S., Germano, I. M., Palmer, J. D., Laack, N. N., Brown, P. D., Gondi, V., Wefel, J. S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893264 · Cited by 70
Caccese, M., Barbot, M., Ceccato, F., Padovan, M., Gardiman, M. P., Fassan, M., Denaro, L., Emanuelli, E., D’Avella, D., Scaroni, C. M., et al. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000856 · Cited by 68
Gubens, M. A., & Davies, M. J. (2019) · PubMed · doi:10.6004/jnccn.2019.5005 · Cited by 68
Hsu, J. H.-M., Chang, P. M.-H., Cheng, T.-S., Kuo, Y.-L., Wu, A. T.-H., Tran, T.-H., Yang, Y.-H., Chen, J.-M., Tsai, Y.-C., Chu, Y.-S., et al. (2019) · Cancers · doi:10.3390/cancers11071003 · Cited by 68
Friedrich, M., Jasinski‐Bergner, S., Lazaridou, M., Subbarayan, K., Massa, C., Tretbar, S., Müeller, A., Handke, D., Biehl, K., Bukur, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02373-1 · Cited by 68
Passaro, A., Attili, I., Morganti, S., Signore, E. D., Gianoncelli, L., Spitaleri, G., Stati, V., Catania, C., Curigliano, G., & de Marinis, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102085 · Cited by 65
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
